Grape King Bio Ltd (TPE:1707)

Market Cap	20.89B
Revenue (ttm)	11.16B
Net Income (ttm)	1.45B
Shares Out	148.14M
EPS (ttm)	9.71
PE Ratio	14.52
Forward PE	12.98
Dividend	8.40 (5.89%)
Ex-Dividend Date	Jun 23, 2025

Volume	262,188
Average Volume	126,819
Open	142.00
Previous Close	142.50
Day's Range	139.00 - 142.00
52-Week Range	132.00 - 163.50
Beta	0.49
RSI	25.88
Earnings Date	May 9, 2025

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distribution; and Original Design Manufacturer/Original Equipment Manufacturer segments. The company offers Chinese herbal, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, weight control, liver care, brain health, eye care, feminine health, and sensual ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2024, Grape King Bio's revenue was 11.16 billion, an increase of 4.93% compared to the previous year's 10.64 billion. Earnings were 1.45 billion, a decrease of -0.30%.